Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Khan S, Lutzky J, Shoushtari AN, Jeter J, Marr B, Olencki TE, Cebulla CM, Abdel-Rahman M, Harbour JW, Sender N, Nesson A, Singh-Kandah S, Hernandez S, King J, Katari MS, Dimapanat L, Izard S, Ambrosini G, Surriga O, Rai AJ, Chiuzan C, Schwartz GK, Carvajal RD.
Khan S, et al.
Front Oncol. 2022 Aug 29;12:976837. doi: 10.3389/fonc.2022.976837. eCollection 2022.
Front Oncol. 2022.
PMID: 36106113
Free PMC article.